Preliminary Clinical Data from Ongoing Phase 1b/2a Clinical Program Presented at New Directions in Biology and Disease of Skeletal Muscle 6th Biennial Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc. a clinical stage biopharmaceutical company developing treatments for patients with Duchenne muscular dystrophy (DMD), today reported that ...

With the HT-100, ANAVIA has developed the most advanced unmanned aerial vehicle (UAV) system in the world. An unmanned helicopter for up to 65 kg of payload and 240 minutes of flight time. It’s the ...

The HT-100 is an all-terrain, day/night, adverse-weather-capable unmanned helicopter UAE-based defence-tech group Edge held a capability demonstration for the ANAVIA HT-100 unmanned helicopter within ...

Investment from Muscular Dystrophy Association Adds to Funding from 15 Other Non-Profit Organizations CAMBRIDGE, MASS. — Akashi Therapeutics, Inc. announced today that the Muscular Dystrophy ...

EDGE’s Swiss subsidiary Anavia has demonstrated what its parent company describes as a “complex flight profile” with an HT-100 unmanned air vehicle for the Brazilian armed forces and police. Recently ...

The United Arab Emirates' (UAE's) Edge Group signed a contract to supply 200 HT-100 and HT-750 unmanned helicopters to the country's Ministry of Defence (MoD) during the Unmanned Systems Exhibition ...

Halo Therapeutics announced that the FDA has granted orphan drug designation for HT-100 (halofuginone) for Duchenne muscular dystrophy (DMD). Plans to initiate a Phase 2 trial in 2012 are underway.